The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

Table 3

Univariate Cox regression analysis of prognostic factors of overall survival.

Parameter	Patients		Overall survival		value
		Percent %	Median, mo	HR, 95% CI
Overall	96	100	24
Gender
Male	78	81.3	25	1.25 (0.66–2.37)	0.490
Female	18	18.7	23	Reference
Years ≥ 65
Yes	26	27.1	23	1.34 (0.78–2.32)	0.293
No	70	72.9	24	Reference
Targeted therapy
Yes	72	75.0	24	1.29 (0.71–2.35)	0.406
No	24	25.0	33	Reference
Clear cell carcinoma
Yes	90	93.8	25	0.56 (0.22–1.41)	0.218
No	6	6.2	17	Reference
Sarcomatoid dedifferentiation
Yes	11	11.5	13	1.74 (0.85–3.53)	0.129
No	85	88.5	25	Reference
T stage
T ≥ 3	41	42.7	24	1.88 (1.13–3.13)	0.015
T < 3	55	57.3	33	Reference
G grade
G ≥ 3	28	29.2	24	1.39 (0.81–2.37)	0.231
G < 3	68	70.8	26	Reference
N
N1-2	9	9.4	24	0.83 (0.36–1.93)	0.660
N0	87	90.6	24	Reference
Lung metastasis
Yes	55	57.3	24	1.60 (0.94–2.73)	0.086
No	41	42.7	33	Reference
Bone metastasis
Yes	39	40.6	29	0.95 (0.57–1.58)	0.846
No	57	59.4	24	Reference
Number of metastatic organs
1	61	63.5	31	Reference
≥2	35	36.5	17	2.25 (1.34–3.78)	0.002
Disease-free interval
≤12 months	53	55.2	19	2.59 (1.50–4.48)	0.001
>12 months	43	44.8	41	Reference
Metastasectomy
Complete resection	31	32.3	52	0.43 (0.23–0.81)	0.009
Incomplete resection	11	11.5	16	1.80 (0.89–3.62)	0.102
No resection	54	56.3	22	Reference

Statistically significant.